title: [Vandetanib, in the management of patients with locally advanced or metastatic medullary thyroid carcinomas].
abstract: Medullary thyroid cancer (MTC) is a rare cancer. Vandetanib, a RET tyrosine-kinase inhibitor, significantly increased progression free survival and is the first treatment approved in France for unresectable, locally advanced or metastatic MTC that is symptomatic or progressive. Most frequents adverse events are diarrhea, folliculitis and asthenia. The prolongation of the QT interval on electrocardiogram is frequent but in the most of cases not clinically relevant. A good selection of the patients who could benefit from this treatment and management of side effect are important for the risk-benefit assessment.
authors.affiliation: Hôpital Saint-Louis, Service médecine nucléaire, 1, avenue Claude-Vellefaud, 75010 Paris, France.
authors.forename: Cecile N
authors.initials: CN
authors.lastname: Chougnet
authors.affiliation: Institut Gustave-Roussy, Service de médecine nucléaire et cancérologie endocrinienne, 114, rue Édouard-Vaillant, 94805 Villejuif, France, Réseau Tuthyref, France.
authors.forename: Martin
authors.initials: M
authors.lastname: Schlumberger
authors.affiliation: Institut Gustave-Roussy, Service de médecine nucléaire et cancérologie endocrinienne, 114, rue Édouard-Vaillant, 94805 Villejuif, France, Réseau Tuthyref, France.
authors.forename: Sophie
authors.initials: S
authors.lastname: Leboulleux
authors.affiliation: Institut Gustave-Roussy, Service de médecine nucléaire et cancérologie endocrinienne, 114, rue Édouard-Vaillant, 94805 Villejuif, France, Réseau Tuthyref, France.
authors.forename: Eric
authors.initials: E
authors.lastname: Baudin
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018276:Carcinoma, Medullary / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology / Q000556:secondary; D018278:Carcinoma, Neuroendocrine; D006801:Humans; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use*; D051096:Proto-Oncogene Proteins c-ret / Q000037:antagonists & inhibitors / Q000235:genetics; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use*; D035583:Rare Diseases / Q000188:drug therapy* / Q000473:pathology; D013964:Thyroid Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D010880:Piperidines; D011799:Quinazolines; D051096:Proto-Oncogene Proteins c-ret; C452423:vandetanib
keywords: medullary thyroid cancer; multiple endocrine neoplasia; targeted therapy; treatment; vandetanib